Case Report

Unusual presentation of primary toxoplasmosis infection in a kidney-transplant patient complicated by an acute left-ventricular failure

Benjamin Hébraud1, Nassim Kamar1,2, Jean-Sébastien Borde1, Marie-Hélène Bessières3, Michel Galinier4 and Lionel Rostaing1,5

1Department of Nephrology, Dialysis and Multiorgan Transplantation, University Hospital, CHU Rangueil, 2INSERM U858, IFR 31, 3Laboratory of Parasitology, 4Department of Cardiology, CHU Rangueil, 1 av. J. Poulhes, TSA 50032 and 5INSERM U563, IFR 30, 330 Avenue de Grande-Bretagne, TSA 40031, 31059 Toulouse Cédex 9, France

Abstract
Although primary toxoplasmosis is a rare event following kidney transplantation, it can be life threatening. This report describes this complication. The patient presented with high-grade fever, haemolytic anaemia and haemophagocytic-syndrome-related pancytopenia. Toxoplasma gondii diagnosis was ascertained by blood and bone-marrow PCR assays. After 6 weeks with Clindamycin plus pyrimethamine therapies and despite negativity of T. gondii blood PCR assay, the patient developed left-ventricular failure. After adding sulfamethoxazole/trimethoprim, ramipril, digoxine, bisoprolol and spironolactone, he progressively recovered. Anti-T. gondii therapy was continued for 6 months. Four years later he received a third kidney allograft: at that time anti-T. gondii antibodies had become negative. The outcome was uneventful despite immunosuppression but with inclusion of sulfamethoxazole/trimethoprim prophylaxis. More than 3 years after the third kidney transplantation the patient has had no toxoplasmosis reactivation. This case report highlights that T. gondii can be the cause of myocarditis in a renal transplant recipient.

Keywords: chronic kidney disease; haemophagocytic syndrome; heart failure; toxoplasmosis; myocarditis

Toxoplasmosis is a worldwide infectious disease caused by the protozoan Toxoplasma gondii. The disease has a favourable outcome in almost all immunocompetent individuals, whereas it can be life threatening in those who are immunocompromised, such as organ-transplant patients [1]. In the latter setting, the disease can result from T. gondii transmission either within the allograft from a seropositive donor into a seronegative recipient [2–4] or via blood [5] from immunocompetent donors. In organ-transplant recipients, the most usual mechanism is the reactivation of latent infection in the recipient [1]. In immunocompromised patients, toxoplasmosis can present as central nervous system (CNS)-related symptoms, chorioretinitis, pneumonitis or multiorgan involvement, presenting with acute respiratory failure or haemodynamic abnormalities similar to septic shock [1]. T. gondii-related haemophagocytic syndrome has also been reported [6,7] as well as T. gondii-related haemolytic anaemia [8–11]. In heart-transplant recipients who are T. gondii seronegative and who receive a T. gondii seropositive allograft, primary toxoplasmosis can present as myocarditis or cardiomyopathy [12]. A case of an unusual presentation of primary toxoplasmosis complicated by a probable toxoplasmosis-induced acute left-ventricular heart failure in a patient with failed renal allograft is reported.

Case report
A male patient, born in 1982, had bilateral congenital kidney hypoplasia and underwent a first kidney transplant, from a living donor, in 1984, and did not experience acute rejection. Immunosuppression consisted of cyclosporine, steroids, plus azathioprine (AZA) until 1989. At this point he lost his allograft due to chronic rejection. A second kidney transplantation, from a deceased donor, was performed in 1990. At that time his toxoplasmosis serology was negative. Immunosuppression included induction therapy with antithymocyte globulins, AZA, steroids and cyclosporine, without methylprednisolone pulses. He progressively developed chronic allograft nephropathy in 2000 and cyclosporine was replaced by tacrolimus, and AZA by mycophenolate mofetil (MMF). In the spring of 2001, his serum creatinine was 522 µmol/L, i.e. calculated creatinine clearance (Cockcroft–Gault formula) was 16 mL/min. The immunosuppression was based on tacrolimus
(4 mg/day, i.e. trough levels of 5 ng/mL), MMF (1 g/day) and prednisolone (0.19 mg/kg/day). In June 2001, daily hyperthermia (above 39°C), maculo-papular skin eruptions, diarrhoea, vomiting and weight loss (~10% within 2 weeks) developed and he was admitted in our unit. The body temperature was 39°C, blood pressure was 150/85 mmHg, with regular pulse at 100/bpm and no oedema was noted. A biological work-up revealed a serum creatinine of 1077 μmol/L and BUN of 43 mmol/L. He had haemolytic anaemia: haemoglobin was 7.8 g/dL, the reticulocyte count was 85 000/mm³, and a low haptoglobin level (<0.06 g/L) and high lactate dehydrogenase (4500 IU/L; N < 500) were found. Schistocytes, antinuclear autoantibodies and a Coomb’s test were all negative. Platelet count was 105 000/mm³ and leucopaenia was 900/mm³. Antitoxoplasma IgM and IgG. Six weeks after anti-toxoplasmosis treatment, toxoplasmosis serology still demonstrated both specific IgM and IgG titres. A repeated blood PCR test for toxoplasmosis remained negative. In addition to Clindamycin and pyrimethamine, sulfamethoxazole/trimethoprim at a dose of 800/120 mg given after each dialysis sessions, ramipril 2.5 mg/day, digoxine three tablets per week, bisoprolol 1.25 mg/day and spironolactone 25 mg/day were added. Finally, the patient was placed on a heart-transplant waiting list. Cardiac function remained poor within the following month but had improved by 2 months later (by November 2001), with a left ventricular ejection fraction of 47% (at which point he was removed from the heart-transplant waiting list). The ejection fraction further increased to 60% by October 2002. Anti-toxoplasmosis therapy was given for a total of 6 months. In March 2005, the patient underwent a successful third kidney transplantation: at this point the toxoplasmosis serology had become negative. He received a T-cell depleting therapy, i.e. antithymocyte globulins, tacrolimus, MMF and steroids. In addition, he also received toxoplasmosis prophylaxis with sulfamethoxazole/trimethoprim (400/80 mg every other day) for 1 year. More than 3 years after his third kidney transplantation no toxoplasmosis reactivation occurred and the serum creatinine was 130 μmol/L.

Discussion

Toxoplasmosis infection is considered to be rare after kidney transplantation. A retrospective survey of 657 consecutive kidney-transplant patients, from 2001 to 2005, revealed only one single case of clinical toxoplasmosis, occurring in an otherwise immunized patient [13]. Iqbal et al. [14] found that only 33.1% of patients had antibodies against T. gondii before transplantation. Within the first year posttransplantation, however, 19 seronegative patients out of 111 seroconverted for T. gondii. Of these, none developed clinical toxoplasmosis. In the seropositive patients, 34 out of 49 patients had an increase in T. gondii antibodies, although none developed toxoplasmosis [14]. In a review article, Renoult et al. reported on 29 kidney transplant patients with posttransplant toxoplasmosis: this originated from the donor in 10 cases; the mortality rate was as high as 64.5% [15].

In kidney-transplant patients toxoplasmosis can be associated in rare cases with haemophagocytic-related pancytopaenia [6,7]. This situation can be life threatening: the diagnosis is based on a bone-marrow aspiration, which can sometimes find tachyzoites that are pathognomonic for toxoplasmosis. Blood and bone-marrow PCR tests are also of value in rapidly detecting T. gondii infections in these circumstances [16], and is now the most sensitive method. Toxoplasmosis has also been associated with haemolytic
anaemia [8–11], though its mechanisms are still poorly understood. Our patient had previously received high amounts of immunosuppressive therapy and two kidney transplants, thus totalling 16 years of immunosuppressive therapy plus an induction therapy with antithymocyte globulins. He presented with both haemophagocytic and haemolytic syndromes and 6 weeks after the start of clindamycin and pyrimethamine he presented with myocarditis. Myocarditis can be suspected from symptoms of fever, sudden onset of global heart failure and biventricular hypokinesia. He fulfilled these three criteria, except that ventricular hypokinesia was located only in the left chamber. No other cause for myocarditis was found. Although we could not directly demonstrate that the myocarditis was related to primary toxoplasmosis infection, we strongly suspected a toxoplasmosis-induced myocarditis based on the recent medical history of the patient, the increase in the anti-T. gondii IgM and IgG titres and the improvement after sulfamethoxazole/trimethoprim therapy had been added to previous therapies. A confirmation by endomyocardial biopsy [17] was not possible. At that time, his blood PCR test for toxoplasmosis was negative, which is not surprising because the parasite, i.e. tachyzoites, can only be detected during the transient parasitaemic phase. After the phase, the parasite forms cysts within the tissues that can only be detected by a biopsy. Tachyzoites are disseminated via the bloodstream and infect many tissues, including the CNS, eye and skeletal and heart muscles. We can speculate that T. gondii may persist in the myocardium even though it is not detected in the blood. Our case report highlights how a patient with a failed allograft can present with the same infectious complication as a transplant patient receiving a high immunosuppressive regimen. Mariani et al. [18] reported a complete atrioventricular block associated with toxoplasmosis myocarditis, but in this case, toxoplasmosis-induced myocarditis diagnosis was based only on positive anti-T. gondii IgM and IgG, and neither the blood PCR test nor the endomyocardial biopsy was performed.

Cases of T. gondii-related clinical myocarditis are very rare but fulminating disseminated toxoplasmosis has been observed after heart transplantation [19]. Moreover, it has been shown among heart-transplant recipients that pre-transplant T. gondii seropositivity is associated with an increased risk of all-cause and cardiac mortality, with an increase in the development of advanced cardiac allograft vasculopathy [20]. The risk of toxoplasmosis in heart-transplant recipients can be decreased by prophylaxis [21–23]. In human immunodeficiency virus (HIV)-positive patients before the era of antiretroviral therapy, a series of necropsies in 182 HIV patients found cardiac toxoplasmosis in 12% (n = 21), of whom one out of seven cases were not associated with CNS involvement. However, in these 21 patients, cardiac toxoplasmosis was suspected in only three [24]. After kidney transplantation, so far, only one case of T. gondii-related myocarditis has been reported in a patient who had T. gondii-related encephalitis; however, this diagnosis was established on postmortem analysis [25].

In immunocompromised patients, the most frequently used successful regimen for toxoplasmosis is a combination of pyrimethamine/sulfadiazine and folinic acid for 4–6 weeks; in HIV patients sulfamethoxazole/trimethoprim appears to be equivalent to the latter regimen [1]. In our patient, we initially replaced sulfadiazine with clindamycin because he presented with end-stage kidney disease because of his failing renal allograft. After 1 month of this therapy he developed cardiac failure, which demonstrates that our therapeutic choice was probably insufficient, but the addition of sulfamethoxazole/trimethoprim therapy rapidly improved the patient’s clinical situation.

Regarding T. gondii prophylaxis, kidney-transplant patients usually receive sulfamethoxazole/trimethoprim as prophylaxis for Pneumocystis jiroveci within the first 6 months posttransplantation and this prophylaxis also prevents toxoplasmosis. After that period, only those who have low TCD4 lymphocyte counts and are at risk for T. gondii, i.e. donor (+)/recipient (−), should be considered for subsequent T. gondii screening and possible long-term prophylaxis.

We conclude that primary toxoplasmosis in kidney-transplant patients can be life-threatening, particularly when complicated by haemophagocytic syndrome and acute left-ventricular heart failure.

Conflict of interest statement. None declared.

References
1. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004; 363: 1965–1976
2. Botterel F, Ichai P, Feray C et al. Disseminated toxoplasmosis, resulting from infection of allograft, after orthotopic liver transplantation: usefulness of quantitative PCR. J Clin Microbiol 2002; 40: 1648–1650
3. Wulf MW, van Creveld R, Portier R et al. Toxoplasmosis after renal transplantation: implications of a missed diagnosis. J Clin Microbiol 2005; 43: 3544–3547
4. Assi MA, Rosenblatt JE, Marshall WF. Donor-transmitted toxoplasmosis in liver transplant recipients: a case report and literature review. Transplant Int 2007; 9: 132–136
5. Kimball AC, Kean BH, Kellner A. The risk of transmitting toxoplasmosis by blood transfusion. Transfusion 1965; 5: 447–451
6. Rostraing L, Baron E, Fillola O et al. Toxoplasmosis in two renal transplant recipients: diagnosis by bone marrow aspiration. Transplant Proc 1995; 27: 1733–1734
7. Segall L, Moal MC, Doucet L et al. Toxoplasmosis-associated haemophagocytic syndrome in renal transplantation. Transplant Int 2006; 19: 78–80
8. Kalderon AE, Kikwaa Y, Bernstein J. Chronic toxoplasmosis associated with severe hemolytic anemia. Case Report and electron microscopic studies. Arch Intern Med 1964; 114: 95–102
9. Blatrix C, Bauxine-Ducrocq H, Couzineau P et al. Toxoplasmosis causing immunologic hemolytic anemia. Presse Med 1967; 75: 333–336
10. Bergin M, Menser MA, Procopis PG et al. Central nervous system toxoplasmosis and hemolytic-uremic syndrome. N Engl J Med 1987; 317: 1540–1541
11. Michelson AD, Lammi AT. Haemolytic anaemia associated with acquired toxoplasmosis. Aust Paediatr J 1984; 20: 333–335
12. Soave R. Prophylaxis strategies for solid-organ transplantation. Clin Infect Dis 2001; 33: S26–S31
13. Valar C, Keitel E, Dal Pra RL et al. Parasitic infection in renal transplant recipients. Transplant Proc 2007; 39: 460–462
14. Iqbal J, Nampoory MR, Johnv KV et al. Determination of antibodies to Toxoplasma gondii and CMV in renal transplant recipients. Transplant Proc 2003; 35: 2703–2705
15. Renoult E, Georges E, Biava MF et al. Toxoplasmosis in kidney transplant recipients: report of six cases and review. Clin Infect Dis 1997; 24: 625–634
16. Aubert D, Foudrinier F, Villena I et al. PCR for diagnosis and follow-up of two cases of disseminated toxoplasmosis after kidney grafting. *J Clin Microbiol* 1996; 34: 1347
17. Wagner FM, Reichenspurner H, Uberfuhr P et al. Toxoplasmosis after heart transplantation: diagnosis by endomyocardial biopsy. *J Heart Lung Transplant* 1994; 13: 916–918
18. Mariani M, Pagani M, Inserra C et al. Complete atrioventricular block associated with toxoplasma myocarditis. *Europace* 2006; 8: 221–223
19. Hermanns B, Brunn A, Schwarz ER et al. Fulminant toxoplasmosis in a heart transplant recipient. *Pathol Res Pract* 2001; 197: 211–215
20. Arora S, Jenum PA, Aukrust P et al. Pre-transplant *Toxoplasma gondii* seropositivity among heart transplant recipients is associated with an increased risk of all-cause and cardiac mortality. *J Am Coll Cardiol* 2007; 50: 1967–1972
21. Baden LR, Katz JT, Franck L et al. Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole. *Transplantation* 2003; 75: 339–343
22. Baran DA, Alwarshetty MM, Alvi S et al. Is toxoplasmosis prophylaxis necessary in cardiac transplantation? Long-term follow-up at two transplant centers. *J Heart Lung Transplant* 2006; 25: 1380–1382
23. Sarchi E, Genco F, Di Matteo A et al. Surveillance of *Toxoplasma gondii* infection in recipients of thoracic solid organ transplants. *New Microbiol* 2007; 30: 299–302
24. Hofman P, Drici MD, Gibelin P et al. Prevalence of toxoplasma myocarditis in patients with the acquired immunodeficiency syndrome. *Br Heart J* 1993; 70: 376–381
25. Schmidt B, Wienke H, Fahrenkamp A et al. Encephalitic and myocardial toxoplasmosis masquerading as cytomegalovirus infection in a renal allograft recipient. *Nephrol Dial Transplant* 1995; 10: 284–286

Received for publication: 17.4.08
Accepted in revised form: 18.9.08